ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on the development of novel antiviral agents, announced today that preclinical data relating to INH-001, one of several potential lead candidates from Inhibitex’s HIV integrase inhibitor program, were presented during this week’s 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI), held February 3-6, 2008, in Boston, MA. Dr. Vasu Nair, Director of the University of Georgia Center for Drug Discovery and head of the Department of Pharmaceutical and Biomedical Sciences, presented data from several preclinical studies of INH-001, which in addition to its pharmacokinetic properties, demonstrated metabolic stability in vitro, multiple mechanisms of action and no significant inhibition of CYP450 proteins.
